Back to Search
Start Over
Safety of treatments for primary Sjogren's syndrome
- Source :
- Expert Opinion on Drug Safety. 15(4):513-524
- Publication Year :
- 2016
-
Abstract
- Introduction: Primary Sjogren's syndrome (pSS) is a disabling auto-immune disease, affecting exocrine glands and several organs.Areas covered: In this review we analyze the safety of therapies used in pSS. Symptomatic treatment is widely applied due to the good supportive effect and good safety profile. Systemic stimulation of tears and saliva can be successful in pSS. However, cumbersome adverse events can influence the tolerability of this therapy. Evidence for the effectiveness of synthetic DMARDs therapies in pSS is limited, while there is a risk of adverse events. Several studies on biologic DMARD treatment of pSS patients have shown promising efficacy and safety results.Expert opinion: The safety of symptomatic treatment of pSS is very good. However, systemic therapy is necessary to achieve long-term relieve and prevention of organ-damage. Synthetic DMARDs have not shown much efficacy in earlier studies, and their benefits do not weigh up to the possible harms, while biologic DMARDs show promising results regarding efficacy and cause mostly mild adverse events. Many questions remain unanswered regarding safety of DMARDs in pSS. There is a need for well designed studies, in which safety should be evaluated in a uniform manner to be able to compare the results between studies.
- Subjects :
- musculoskeletal diseases
Primary Sjogren's syndrome
medicine.medical_specialty
DRY EYE SYMPTOMS
drug safety
Drug-Related Side Effects and Adverse Reactions
AUTOLOGOUS SERUM APPLICATION
Placebo-controlled study
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
Disease
INTERSTITIAL LUNG-DISEASE
PLACEBO-CONTROLLED TRIAL
Systemic therapy
CONNECTIVE-TISSUE DISEASES
law.invention
synthetic DMARDs
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
stomatognathic system
law
medicine
Humans
RANDOMIZED-CLINICAL-TRIAL
Pharmacology (medical)
030212 general & internal medicine
SYSTEMIC-LUPUS-ERYTHEMATOSUS
Intensive care medicine
Adverse effect
030203 arthritis & rheumatology
business.industry
GOBLET CELL-DENSITY
Progressive multifocal leukoencephalopathy
General Medicine
medicine.disease
eye diseases
Antirheumatic Agents
stomatognathic diseases
Sjogren's Syndrome
topical treatment
Tolerability
Physical therapy
biologic DMARDs
Safety
business
Immunosuppressive Agents
DYSFUNCTIONAL TEAR SYNDROME
Subjects
Details
- Language :
- English
- ISSN :
- 14740338
- Volume :
- 15
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Drug Safety
- Accession number :
- edsair.doi.dedup.....a7395b48ea01363a6566b1b03c86ba09